Drugs / RAPA-201
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05144698 | Aug 2021 → Jan 2026 overdue | esophageal squamous cell carcinoma, laryngeal squamous cell carcinoma, lung cancer, melanoma +3 | Rapa Therapeutics LLC | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06708455 | Mar 2027 → Mar 2029 expected | metastatic melanoma | Rapa Therapeutics LLC | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04176380 | Dec 2020 → Jan 2023 | refractory plasma cell neoplasm | Rapa Therapeutics LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAPA-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04176380 ↗ |
| Modality | Cell therapy | “Polyclonal autologous T cells that are epigenetically reprogrammed through mTOR inhibition and IFN-α polarization (RAPA-201) represent a novel approach to the adoptive T cell...” PMID 39875173 ↗ Jan 2025 |